A study of concurrent radiochemotherapy with paclitaxel in glioblastoma multiforme

P. K. Julka, B. S. Awasthy, G. K. Rath, S. Agarwal, T. Varna, A. K. Mahapatra, R. Singh

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Despite advances in neurosurgery and radiotherapy, the prognosis of patients with glioblastoma multiforme remains poor. Reports in the literature about the radiosensitizing properties of paclitaxel stimulated the authors to conduct a study using paclitaxel concurrently with radiation in a group of 18 patients who had residual disease postoperatively. Paclitaxel was delivered weekly as an intravenous infusion in a dose of 60 mg/m2 along with radiation to the primary lesion. A total of 108 cycles of paclitaxel was given. All the patients tolerated the treatment well. The main side effects were haematological, and neuropathy which was self-limiting. The overall 1-year survival rate was 70%, with 12 patients alive at 13 months. The median survival has not yet been reached although it is more than 13 months. Thus, paclitaxel can be safely delivered concomitantly with radiation in patients with glioblastoma multiforme. Larger, randomized trials are required to establish the comparative efficacy of paclitaxel as a radiosensitizer in glioblastoma multiforme.

Original languageEnglish
Pages (from-to)84-87
Number of pages4
JournalAustralasian Radiology
Volume44
Issue number1
DOIs
Publication statusPublished - Feb 1 2000

Fingerprint

Chemoradiotherapy
Glioblastoma
Paclitaxel
Radiation
Neurosurgery
Intravenous Infusions
Radiotherapy
Survival Rate
Survival

Keywords

  • Concurrent
  • Glioblastoma
  • Multiforme
  • Paclitaxel
  • Radiotherapy

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

Julka, P. K., Awasthy, B. S., Rath, G. K., Agarwal, S., Varna, T., Mahapatra, A. K., & Singh, R. (2000). A study of concurrent radiochemotherapy with paclitaxel in glioblastoma multiforme. Australasian Radiology, 44(1), 84-87. https://doi.org/10.1046/j.1440-1673.2000.00776.x

A study of concurrent radiochemotherapy with paclitaxel in glioblastoma multiforme. / Julka, P. K.; Awasthy, B. S.; Rath, G. K.; Agarwal, S.; Varna, T.; Mahapatra, A. K.; Singh, R.

In: Australasian Radiology, Vol. 44, No. 1, 01.02.2000, p. 84-87.

Research output: Contribution to journalArticle

Julka, PK, Awasthy, BS, Rath, GK, Agarwal, S, Varna, T, Mahapatra, AK & Singh, R 2000, 'A study of concurrent radiochemotherapy with paclitaxel in glioblastoma multiforme', Australasian Radiology, vol. 44, no. 1, pp. 84-87. https://doi.org/10.1046/j.1440-1673.2000.00776.x
Julka, P. K. ; Awasthy, B. S. ; Rath, G. K. ; Agarwal, S. ; Varna, T. ; Mahapatra, A. K. ; Singh, R. / A study of concurrent radiochemotherapy with paclitaxel in glioblastoma multiforme. In: Australasian Radiology. 2000 ; Vol. 44, No. 1. pp. 84-87.
@article{5fb60fa5d16040b5b064b3bbe557eeca,
title = "A study of concurrent radiochemotherapy with paclitaxel in glioblastoma multiforme",
abstract = "Despite advances in neurosurgery and radiotherapy, the prognosis of patients with glioblastoma multiforme remains poor. Reports in the literature about the radiosensitizing properties of paclitaxel stimulated the authors to conduct a study using paclitaxel concurrently with radiation in a group of 18 patients who had residual disease postoperatively. Paclitaxel was delivered weekly as an intravenous infusion in a dose of 60 mg/m2 along with radiation to the primary lesion. A total of 108 cycles of paclitaxel was given. All the patients tolerated the treatment well. The main side effects were haematological, and neuropathy which was self-limiting. The overall 1-year survival rate was 70{\%}, with 12 patients alive at 13 months. The median survival has not yet been reached although it is more than 13 months. Thus, paclitaxel can be safely delivered concomitantly with radiation in patients with glioblastoma multiforme. Larger, randomized trials are required to establish the comparative efficacy of paclitaxel as a radiosensitizer in glioblastoma multiforme.",
keywords = "Concurrent, Glioblastoma, Multiforme, Paclitaxel, Radiotherapy",
author = "Julka, {P. K.} and Awasthy, {B. S.} and Rath, {G. K.} and S. Agarwal and T. Varna and Mahapatra, {A. K.} and R. Singh",
year = "2000",
month = "2",
day = "1",
doi = "10.1046/j.1440-1673.2000.00776.x",
language = "English",
volume = "44",
pages = "84--87",
journal = "Journal of Medical Imaging and Radiation Oncology",
issn = "1754-9477",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - A study of concurrent radiochemotherapy with paclitaxel in glioblastoma multiforme

AU - Julka, P. K.

AU - Awasthy, B. S.

AU - Rath, G. K.

AU - Agarwal, S.

AU - Varna, T.

AU - Mahapatra, A. K.

AU - Singh, R.

PY - 2000/2/1

Y1 - 2000/2/1

N2 - Despite advances in neurosurgery and radiotherapy, the prognosis of patients with glioblastoma multiforme remains poor. Reports in the literature about the radiosensitizing properties of paclitaxel stimulated the authors to conduct a study using paclitaxel concurrently with radiation in a group of 18 patients who had residual disease postoperatively. Paclitaxel was delivered weekly as an intravenous infusion in a dose of 60 mg/m2 along with radiation to the primary lesion. A total of 108 cycles of paclitaxel was given. All the patients tolerated the treatment well. The main side effects were haematological, and neuropathy which was self-limiting. The overall 1-year survival rate was 70%, with 12 patients alive at 13 months. The median survival has not yet been reached although it is more than 13 months. Thus, paclitaxel can be safely delivered concomitantly with radiation in patients with glioblastoma multiforme. Larger, randomized trials are required to establish the comparative efficacy of paclitaxel as a radiosensitizer in glioblastoma multiforme.

AB - Despite advances in neurosurgery and radiotherapy, the prognosis of patients with glioblastoma multiforme remains poor. Reports in the literature about the radiosensitizing properties of paclitaxel stimulated the authors to conduct a study using paclitaxel concurrently with radiation in a group of 18 patients who had residual disease postoperatively. Paclitaxel was delivered weekly as an intravenous infusion in a dose of 60 mg/m2 along with radiation to the primary lesion. A total of 108 cycles of paclitaxel was given. All the patients tolerated the treatment well. The main side effects were haematological, and neuropathy which was self-limiting. The overall 1-year survival rate was 70%, with 12 patients alive at 13 months. The median survival has not yet been reached although it is more than 13 months. Thus, paclitaxel can be safely delivered concomitantly with radiation in patients with glioblastoma multiforme. Larger, randomized trials are required to establish the comparative efficacy of paclitaxel as a radiosensitizer in glioblastoma multiforme.

KW - Concurrent

KW - Glioblastoma

KW - Multiforme

KW - Paclitaxel

KW - Radiotherapy

UR - http://www.scopus.com/inward/record.url?scp=0034113710&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034113710&partnerID=8YFLogxK

U2 - 10.1046/j.1440-1673.2000.00776.x

DO - 10.1046/j.1440-1673.2000.00776.x

M3 - Article

VL - 44

SP - 84

EP - 87

JO - Journal of Medical Imaging and Radiation Oncology

JF - Journal of Medical Imaging and Radiation Oncology

SN - 1754-9477

IS - 1

ER -